143 related articles for article (PubMed ID: 29203265)
1. A low blood copper concentration is a co-morbidity burden factor in Parkinson's disease development.
Ilyechova EY; Miliukhina IV; Orlov IA; Muruzheva ZM; Puchkova LV; Karpenko MN
Neurosci Res; 2018 Oct; 135():54-62. PubMed ID: 29203265
[TBL] [Abstract][Full Text] [Related]
2. Role of Copper Dyshomeostasis in the Pathogenesis of Parkinson's Disease.
Karpenko MN; Ilyicheva EY; Muruzheva ZM; Milyukhina IV; Orlov YA; Puchkova LV
Bull Exp Biol Med; 2018 Mar; 164(5):596-600. PubMed ID: 29577200
[TBL] [Abstract][Full Text] [Related]
3. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease.
Tórsdóttir G; Kristinsson J; Sveinbjörnsdóttir S; Snaedal J; Jóhannesson T
Pharmacol Toxicol; 1999 Nov; 85(5):239-43. PubMed ID: 10608487
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of zinc and copper in patients with Parkinson's disease.
Jiménez-Jiménez FJ; Fernández-Calle P; Martínez-Vanaclocha M; Herrero E; Molina JA; Vázquez A; Codoceo R
J Neurol Sci; 1992 Oct; 112(1-2):30-3. PubMed ID: 1469436
[TBL] [Abstract][Full Text] [Related]
5. Copper and zinc concentrations and the activities of ceruloplasmin and superoxide dismutase in atherosclerosis obliterans.
Iskra M; Majewski W
Biol Trace Elem Res; 2000 Jan; 73(1):55-65. PubMed ID: 10949969
[TBL] [Abstract][Full Text] [Related]
6. Copper, ceruloplasmin and superoxide dismutase (SOD) in amyotrophic lateral sclerosis.
Tórsdóttir G; Kristinsson J; Gudmundsson G; Snaedal J; Jóhannesson T
Pharmacol Toxicol; 2000 Sep; 87(3):126-30. PubMed ID: 11068853
[TBL] [Abstract][Full Text] [Related]
7. Serum copper, zinc, ceruloplasmin and superoxide dismutase in Thai overweight and obese.
Tungtrongchitr R; Pongpaew P; Phonrat B; Tungtrongchitr A; Viroonudomphol D; Vudhivai N; Schelp FP
J Med Assoc Thai; 2003 Jun; 86(6):543-51. PubMed ID: 12924803
[TBL] [Abstract][Full Text] [Related]
8. Copper, ceruloplasmin and superoxide dismutase (SOD1) in patients with Down's syndrome.
Tórsdóttir G; Kristinsson J; Hreidarsson S; Snaedal J; Jóhannesson T
Pharmacol Toxicol; 2001 Dec; 89(6):320-5. PubMed ID: 11903959
[TBL] [Abstract][Full Text] [Related]
9. [Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD)].
Johannesson T; Kristinsson J; Torsdottir G; Snaedal J
Laeknabladid; 2012 Oct; 98(10):531-7. PubMed ID: 23043066
[TBL] [Abstract][Full Text] [Related]
10. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: a follow-up study.
Tórsdóttir G; Sveinbjörnsdóttir S; Kristinsson J; Snaedal J; Jóhannesson T
J Neurol Sci; 2006 Feb; 241(1-2):53-8. PubMed ID: 16352311
[TBL] [Abstract][Full Text] [Related]
11. Serum microRNA-133b is associated with low ceruloplasmin levels in Parkinson's disease.
Zhao N; Jin L; Fei G; Zheng Z; Zhong C
Parkinsonism Relat Disord; 2014 Nov; 20(11):1177-80. PubMed ID: 25218846
[TBL] [Abstract][Full Text] [Related]
12. Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease.
Bharucha KJ; Friedman JK; Vincent AS; Ross ED
J Neurol; 2008 Dec; 255(12):1957-62. PubMed ID: 19159062
[TBL] [Abstract][Full Text] [Related]
13. Predictive association of copper metabolism proteins with Alzheimer's disease and Parkinson's disease: a preliminary perspective.
Pal A; Kumar A; Prasad R
Biometals; 2014 Feb; 27(1):25-31. PubMed ID: 24435851
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives.
Arnal N; Cristalli DO; de Alaniz MJ; Marra CA
Brain Res; 2010 Mar; 1319():118-30. PubMed ID: 20026314
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities in Copper Status Associated with an Elevated Risk of Parkinson's Phenotype Development.
Karpenko MN; Muruzheva ZM; Ilyechova EY; Babich PS; Puchkova LV
Antioxidants (Basel); 2023 Aug; 12(9):. PubMed ID: 37759957
[TBL] [Abstract][Full Text] [Related]
16. Serum superoxide dismutase 3 (extracellular superoxide dismutase) activity is a sensitive indicator of Cu status in rats.
Johnson WT; Johnson LA; Lukaski HC
J Nutr Biochem; 2005 Nov; 16(11):682-92. PubMed ID: 16081273
[TBL] [Abstract][Full Text] [Related]
17. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease . a case-control study.
Snaedal J; Kristinsson J; Gunnarsdóttir S; Olafsdóttir ; Baldvinsson M; Jóhannesson T
Dement Geriatr Cogn Disord; 1998; 9(5):239-42. PubMed ID: 9701674
[TBL] [Abstract][Full Text] [Related]
18. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.
Boll MC; Sotelo J; Otero E; Alcaraz-Zubeldia M; Rios C
Neurosci Lett; 1999 Apr; 265(3):155-8. PubMed ID: 10327154
[TBL] [Abstract][Full Text] [Related]
19. Association between sex, systemic iron variation and probability of Parkinson's disease.
Mariani S; Ventriglia M; Simonelli I; Bucossi S; Siotto M; Donno S; Vernieri F; Squitti R
Int J Neurosci; 2016; 126(4):354-60. PubMed ID: 26000822
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome c oxidase, Cu,Zn-superoxide dismutase, and ceruloplasmin activities in copper-deficient bovines.
Cerone SI; Sansinanea AS; Streitenberger SA; Garcia MC; Auza NJ
Biol Trace Elem Res; 2000 Mar; 73(3):269-78. PubMed ID: 11049217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
